Which ARV drug is included to prevent mother-to-child transmission during breastfeeding?
Appeared in: AIIMS CRE 2025
Explanation
Nevirapine is the antiretroviral drug recommended by the World Health Organization (WHO) for extended daily prophylaxis in infants who are breastfeeding from an HIV-positive mother.
This strategy is designed to provide a protective barrier against the HIV virus that can be transmitted through breast milk.
While initial prophylaxis might use other agents, Nevirapine is the standard for the entire duration of breastfeeding to minimize postnatal transmission risk.
Why Other Options Were Wrong
Option A: Zidovudine is primarily used for the initial 4-6 weeks of neonatal prophylaxis, not for the entire extended duration of breastfeeding.
Option C: Efavirenz is a key component of the antiretroviral therapy (ART) regimen for the mother, not for prophylaxis in the infant.
Option D: Stavudine is an older ARV drug that has been largely phased out of first-line treatment protocols due to its significant and severe side effect profile.
Related Visual
Visual 1: Flowchart: PMTCT algorithm for a breastfeeding infant, showing maternal ART, initial 6-week infant prophylaxis, and extended Nevirapine prophylaxis until cessation of breastfeeding.
Visual 2: Infographic: Comparing the roles of different ARVs in PMTCT, clearly distinguishing between maternal treatment and infant prophylaxis.
Clinical Relevance
Nursing practice connection: Use the key finding related to Pharmacological prophylaxis for Prevention of Mother-to-Child Transmission (PMTCT) of HIV to guide bedside assessment, documentation, and the next nursing action.
Nurses play a critical role in educating the mother about the importance of strict adherence to both her own ART and the infant's daily Nevirapine prophylaxis.
Counseling on feeding choices is vital. Nurses should support exclusive breastfeeding for the first 6 months while on prophylaxis, as mixed feeding can increase transmission risk.
Monitoring for potential side effects in the infant, such as skin rash (a known side effect of Nevirapine), is a key nursing responsibility.
How to Approach the Question
First, identify the core components of the question: 'ARV drug', 'prevent mother-to-child transmission', and the specific context 'during breastfeeding'.
Recognize that PMTCT involves both treating the mother and providing prophylaxis to the infant.
Differentiate between the initial prophylaxis given to all exposed newborns (often Zidovudine for 4-6 weeks) and the extended prophylaxis required specifically for the duration of breastfeeding.
Recall or deduce that Nevirapine is the standard agent for this extended prophylaxis period.
Evaluate each option: eliminate drugs used for maternal treatment (Efavirenz) and outdated drugs (Stavudine), and differentiate between initial (Zidovudine) and extended breastfeeding prophylaxis (Nevirapine).
Concept Tested & Keywords
Concept Tested: Pharmacological prophylaxis for Prevention of Mother-to-Child Transmission (PMTCT) of HIV.
Stem keywords: ARV drug, mother-to-child transmission, breastfeeding
Lead-in keywords: Which
Clinical cues: Age/sex group narrows the expected diagnosis, intervention, or normal reference range.
Negative lead-in flag: false
Question ID
Q0B0bevcdhEG0O2dAhzA6Y
Practise the full AIIMS CRE 2025
Attempt every question from this paper in a timed mock, then review the full solution for each one.